Mother and child at health care professionals office

Evidence

insulin lispro logo

Head-to-head studies Insulin lispro Sanofi vs Humalog

Similar PK/PD profile chart

Similar PK/PD profile1

PK/PD profiles in the biosimilar, Insulin lispro Sanofi, were similar to the EU-approved Humalog in adult males with Type 1 diabetes1

Download clinical summary

Similar mean HbA1C reduction2,3

Similar mean HbA1C reduction from baseline to Week 26 in Insulin lispro Sanofi and Humalog groups, in both Type 1 and Type 2 diabetes2,3

 

Download clinical summary

Similar mean HbA1c reduction chart

Type 1 diabetes and Type 2 diabetes chart

Similar long-term safety and tolerability profiles2,3

Similar rates of patients with at least one hypoglycaemic event, regardless of the category, was observed in both Insulin lispro Sanofi and Humalog groups in Type 1 and Type 2 diabetes2,3

Download clinical summary

Abbreviations:
CI, confidence interval; EU, European Union; GIR, glucose infusion rate; HbA1c, glycated haemoglobin; INS, plasma insulin lispro concentration; PD, pharmacodynamic; PK, pharmacokinetic; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UK, United Kingdom.

References:

  1. Kapitza C, et al. Diabetes Obes Metab. 2017;19(5):622–7
  2. Garg SK, et al. Diabetes Technol Ther. 2017;19(9):516–26
  3. Derwahl K, et al. Diabetes Technol Ther. 2018;20(1):1–10
Lady talking on phone

Always up to date?

Webinars, evidence, expert video’s, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.

This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy.
By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.
Accept and close